Intracystic injection of OK-432: a new sclerosing therapy for cystic hygroma in children

Br J Surg. 1987 Aug;74(8):690-1. doi: 10.1002/bjs.1800740812.


Nine patients with cystic hygroma were treated with a new sclerosing therapy consisting of intracystic injection of OK-432 (group A Streptococcus pyogenes of human origin). Favourable results including complete regression in eight patients and marked regression in one were observed within 2-3 months without serious side-effects except for fever of 2-3 days' duration and local inflammatory reaction lasting for 3-4 days. Local inflammatory reaction did not cause any damage to the overlying skin and did not lead to scar formation.

MeSH terms

  • Abdominal Neoplasms / therapy
  • Adolescent
  • Biological Products / administration & dosage*
  • Child, Preschool
  • Female
  • Head and Neck Neoplasms / therapy
  • Humans
  • Infant
  • Lymphangioma / therapy*
  • Male
  • Picibanil / administration & dosage*
  • Picibanil / therapeutic use
  • Retroperitoneal Neoplasms / therapy
  • Sclerosing Solutions / administration & dosage*
  • Sclerosing Solutions / therapeutic use


  • Biological Products
  • Sclerosing Solutions
  • Picibanil